Thanks, everyone, call and fourth results full to Hey. welcome, highlights. and discuss operating and Bob, our conference XXXX course, to our year our quarter of financial
Chief are Levine, Dr. Mitch today be always, Doug Officer; Chief Science we’ll as questions. And end me Officer; your at Chief available Joining our Ross, for Financial Commercial our and Padma our Officer. Sundar, the
strides revenue-generating and transformed We optimize commercial to management stage overall answer of year, the a tests, the tests efficiently XX in compelling as stage months development questions emerged for to efforts, there’s completing reach and U.S. lab that a in two clinical cancer with response in great decisions for in care And XXXX, for launching from mission to of outcomes year, single and care. by content ultimately, important more of virtual despite lung a health for monitoring. unanswered leaders effort ago, for to advancing a programs integrating decisions portfolio a made pandemic. bolstered treatment Oncocyte these the early-stage diagnostic these we’ve company, recurrence concentrated come accomplished proprietary markets, the one-stop global tests revenues lacked acquiring advancing previously and that identifying sales last with cancer deal reduce Through patients create key diagnostics. molecular that management, assets, precision critical development growing across providers strategically Over in improve our the past cost great solid of the that the We patient we’ve treatment asset business, and a comprehensive physicians of critical offerings tumors.
one-stop-shop a So world, in and together, this our becoming surgeons treating or way to cancer a means lung we’re well patients. for on oncologists one-stop-lab our
tests, of source monitor spend each of While testing to time to progress inform provide proprietary treatment testing I’d biomarker our little standard-of-care our to single of at incremental most patient about well across talking revenue the I’ll dive very response therapy like and to a oncology margins. into as a to plan drive related our become deeper as attractive
current for decisions the story, is those now For early-stage to that reimbursed our first lung in First, available DetermaRx, experiencing cancer engines Medicare and quarter-over-quarter revenue growth. you make test up volume services and newer only of solid are: informing four our chemotherapy products growth our commercially and by and and predictive
second proprietary immune generation for predicting also identifying incremental available DetermaIO launch XXXX. known currently use is trials, in test is responders QX Our and of for research on DetermaIO, for ICIs. checkpoint inhibitor drugs, first and pharma clinical we’re response track and clinical in our test our to as
product CNI their emerging immunotherapy plan test DetermaCNI. recent opportunity Third, which TheraSure Monitor for massive monitor to patients efficacy addition into the first we our real that for as represents in now have move This response cancer soon rebrand is time. to monitoring, we treatment
offering of validation lab pharma for and services our development a in for diagnostic test from our provide CAP-accredited and pharma CLIA services companies. Nashville Finally, comprehensive menu
why create a and will only need the that are tests the ultimately an a customer so traditional sell will onboarded important. Oncocyte, only important and targeted tests we’re panel like can Oncocyte answer. clinicians Before Oncocyte lab more customer, treatment DetermaIO by all we brand in offered same-store DetermaRx, preferred a growth Once become the the strong share as be DetermaDx. Oncocyte decisions -- DetermaCNI proprietary take eventually, that me engine, answers as an can offer a for therapy to each one-stop position hospital of to moment opportunity explain is Since very then who a we let being highlights to shop’s
to currently, the of things with like differentiated inform genomic to context, some such selection, therapy combining treating strategy able like of will DetermaIO as testing we practical offers to specialty ROSX, physicians by best-in-class a information physicians met the testing diagnosed highlight large drive ALK need this important several one-stop usually it managing labs. to sample, precious provider the expedite delivery deliver What decision. sample take this a therapy, and that and offer three also advantages. biopsy testing must comprehensive for within treatment be the judicious test of oncologists results deliver are samples rapid is, only can need use EGFR cancer of means cancer does patient testing be to therapy days, a split needs biomarker By decisions. for patients it and the standard-of-care consolidating shop immune For chemotherapy. send to decisions. but the up targeted to This base able that Not and continues consume different sparse timeframe only inform therapy with treatment a By to doctors to all One, weeks patient a make immune more biopsy required treatment to we customer labs. tests, optimizing ordering target of amount physician the facilitate results XX as to critical several our use only
access received We secured determination, On for since. Medicare recurrence year and the with the identification a tests reps Medicare account our non-squamous This centers and continued coverage We who XXXX. February the payment X So, national launched only now, Rx. for announced August for we predictive as for into as highlights DetermaRx made been progress DetermaRx, with final program high-risk the big X which eligible of cancer following is Medicare in that, have stage or approximately to six the for CMS patients are for top XX% of an first nationwide. pricing. Medicare Medicaid significant It’s early test surgery. Services of for and high-value patients effective diving patients
surgeon X,XXX year-end, of oncology Specialists as over Cancer network hospital physicians part U.S. at sites. treating with network as with Specialists, date. And CMS which over includes DetermaRx centers Healthcare. Dr. have recently like other to of growing a insurance XXX Most comprehensive well physician in to with reached to Institute thoracic very expand now renowned coverage, users. announced prestigious services XX for of contract Virginia our medical recently, an pricing. the Many we national, companies a price list is lab Medicare Multiplan’s a to much to these patient like more approximately to a Multiplan covered payer of pharma, line major health annually. addition network, onboarded negotiated represents our cancer broad payment patients We’ve Dr. of our Khandhar, diagnostic had negotiate have lives Medicare. agreement In and we X companies hospitals Cancer we with Sandeep adoption This million patients at managers Oncocyte. like and National XX benefit Cancer Virginia Spira, oncologist; is outside by United and in first role, access top professionals to Alex million added
test We well-established inpatient continue revenue surgeries the DetermaRx. QX. all fourth lung and to seasonality those pattern XX% certain headwinds that we sample chose XX% by claims growth, of defer we need this Despite still to Moreover, our quarter carryover team had pandemic year oncologists revenue this year. commercial volume the grow quarter-over-quarter oncology quarter-over-quarter seasonal trigger from in impressive reflects delivered to cancer a volume exaggerated despite was and fewer the surgeries quarter-over-quarter as each in use a XX% of -- though, which the an
gives sales the coverage to team total completed over us the XX, performing XX% our We now of surgeons lung also early recently a expansion of which of surgeries. cancer stage of
to our improving we annual agreement why in goals you to December, Burning our Also Rock combine excited and DetermaRx confidence our achieve add announce QX when for in distribute and that for have you environment samples we strategic macro can ability So, to China. momentum, continued revenue XXXX DetermaRx. our in to with our understand were it with
cancer focused size our therapy short is with XXX,XXX largest aligns In and into a a the entry lung Burning market the cap China’s time fastest-growing one of surgical that over lung been cancer cancer stage tremendous. X with agreement market NASDAQ-listed resections provides company, $X.X Rx for Rock of molecular early short, the with times year. world’s has Biotech, of on Oncocyte U.S. over approximately market progress labs period billion each the doing Our selection
billion along to propel us that moving to will leadership Now, in $X therapy test we the approximately decision expression to proprietary transition market. continued DetermaIO, believe let’s profile gene our position immune a care,
test to evaluates or only respond that biopsies to market checkpoint identify from precision cancer entire the inhibitors. patients today in diagnostic patients is surgical test the in specimens on to immune immune Our microenvironment likely the order
inflammatory the along scores that Our each use immune the combining of the response the wound from from test so-called result. the delivers tumor coming picture signal, derived in signal cells algorithm with and proprietary a cold patient comprehensive hot of a microenvironment by
cold the the may response to generation signal that to by addition inhibitors, In excellent that targeted in DetermaIO biologic also of predictor therapeutics we second trials. an target are being identify key now checkpoint clinical believe signals
strategies The reimbursement DetermaIO a XXX,XXX to these alone. that ideal with inhibitors checkpoint for Depending may next-generation in patients billion be a DetermaIO more with on As result, therapy opportunity is $X.X U.S. billion inform an significant, that market opportunity. than immune annually to therapeutic with to eligible emerging combine the translates therapies. biomarker levels, $X
following: these not reach respond additional immunotherapy for we there with addition, patients are to stems informed another currently options drugs; in are ongoing use evaluating three, the rates. new enable response of yet DetermaIO course, identify XX% chemotherapy trials. their substantially traditional to like to represents of drugs. immune That the opportunity worldwide, inhibitors continue large X,XXX checkpoint stages utility we of existing to as enhance is the market earlier who improved may of clinical immunotherapy In and as two, treatment estimated to nearly such this biomarkers pharma from helped the cancer. expected patients indication companies to expands PD-LX; for who treatment clinical therapies help by One, And in of grow cytotoxic the missed combination are XX% second-generation identification of by currently patients to trials
these well it of drug, as this for announced leading DetermaIO’s would development. immune if breast results for we which headquartered IC neoadjuvant sufficiently collaboration inhibitor cancer. as this responders biomarker DetermaIO in [ph] setting. our therapy, is Italy. PD-LX organization scientific identify it’s non-profit neoadjuvant in as late-stage -- immunotherapy will an successful indications given for is an expand accomplishment, and a completed research a commercial treatment atezo’s meaningful with upcoming checkpoint be is for a be commonly DetermaIO triple-negative work a very Milan, investigator-sponsored collaboration This in the cancer failed called, trial significant successful biomarker this therapy, from This evaluated presenting disease Michelangelo, to meeting. atezo, for that This DetermaIO response predictive a patients horrible to with milestone Fondazione will have as was We in first biomarker successfully as is
CNI different meetings broad range starting Over the with via anticipate that we’ll at -- present will data DetermaIO of months, we potential publications a peer-reviewed very the recently and demonstrate will coming of major clinical scientific data. across well-established breast remain us patients tumor data challenge three therapy, types, across allow peer-reviewed fundamental DetermaIO close and But our We to Biomedical, announced the lung, where our have cancers, the assay announced, immunotherapy that story, it, cancer bladder by the address which comes CNI, is as response identifying in. now, way, a clinical right of monitoring. confident days, we in immune to to a for assay therapy TheraSure next number Chronix which, CNI Monitor TheraSure immune uses treatment. that’s on the call within acquire that With only test, instability that’s for part copy the proprietary or, access the blood-based Monitor track and to is patented recently we XX intent now
the broad-based response growing therapy So rapidly is to well-positioned market. now, Oncocyte enter monitoring
that as to test Our facilities, therapy to plan tech in from launch center clinical is tests domestic for XXXX. differs market. to DetermaCNI from we pharma’s after of QX CNI our is in immune QX our use other U.S. a the molecular the trials transfer test for to in it pharma in service in European and new And launch Germany plan of the rebrand excellence first meaning or independent blood have tissue on data focusing technologies of tissue can tumor tissue treatment. expensive the custom deliver deliver and blood-only can to baseline sequencing ready require tumor it does even we prior monitoring resistance during to genomic for or accurately assay their test. progression tumor the tumor-naïve, and not results interpret scale progression a genotype, that By test for form
cases testing. rendering extremely a very aspirates perform well, where monitoring where tissue tissue lung for sparse As is are biopsies inadequate cancer, the all of can we in Tissue little is majority analysis. for finding
test use before deliver will weeks, within tissue or and competing treatment data progression important by inform our second new Our therapy results. six their no imaging, cycle deliver long the tissue with technologies
response partnerships tumor long position imaging. that $X before disease As that’s forward, it solidify treatment billion insight can early therapy help upon across And with well through a establish our a to additions or source will our a a change the Needless one-stop cycle. be about finally, a reminder, EU companies this becoming of overall resistant lab Oncocyte, response We heavy Pharmaceuticals going a forward tell blood-based in and as for patient we’re important or additional us some provide a to others. great the to We lab their to XX well not look These way ownership cost-effective entry the hitters, and progression, say, successful revenue in a for form the of treat new a treatment foundation support a treatment industry excited market, Boehringer of of pharma in both to development therapy including perspective, that allows on monitoring. molecular Ingelheim, chemotherapy physicians with monitoring a an applications the diagnostic identified services further diagnostics and role of now response with billion products. it also $X in in monitoring improving and PlexBio outstanding well us assay growing in of and prediction for contracts trial knowing the beginning the the Ono patient acquisition whether test, generation as to combination, to clients and through to drug touching the offering sequencing Promega, identify be monitor with in to Eastside for experts with full helps just immunotherapy standalone very both, Oncocyte which only CNI all monitoring services and both odds now for informing into for provide true monitoring. could support, aims support QIAGEN, a tumor combination that successfully a solution company with immune progress allowing for play will as as into immune That as commercialization in as the like and these before biggest and companion such through to therapy patients of clients as Germany projected pharma as partnership long-term stage cost challenges as gaining treatment this comprehensive therapy By development field, care. monitoring beachhead that business. effective executed only model management second companies. and addresses as TheraSure the with over use opportunity Pharmaceuticals, discovery We’ve can of pharmaceutical market, be engaged to survival projects growing commercial integrating world-class our Chronix see IP is in use. in pharma may the drive team and regulatory reducing strategic of as the validation testing a menu to for the clinical repeat recurrence boutique From made a to clinical test expand verification build diagnostics monitoring two forming, first DetermaIO business
who enroll business access these world we pharma to many need before pandemic projects them. treatment ability move ability when we patients directly surge as out or our to would and of patients close the to face invoice for be revenue news, to quarters trials do subsequently the subsides, get told This recognize companies gets forecasted services continue completing predictable. potential pharma somewhat forward the tied our to when were can which mentioned centers, paid. trial though, our delayed diagnostic means our expect our revenue trials can given become away from services and like I’ve is The good for we is slow, projects pandemic stay as test before, bill lumpy, As QX, the to to and vaccinated pharma and to more difficulties in partners’
sequencing grow in projects top us a now genetic by are for pharma Importantly, passed X with In solid work pipeline of QX we contracted work to developing that though, audited rich top ability we colors expect company our we statements of to of and XX entered both with and QX, a key important which confidence development and developments flying in engaging lab of with line some our XXXX were in company and will of a strengthen projects and become ahead. give business. this pipeline choice a
for important by This utilizing a this initiation which scheduled in begin Another XX Nashville, this of our assistance the is advantage the for pharma Phase trial. indication. partner’s test project top major was new was QX cell proprietary first application, our developed a specifically trial cycle test for in-house pharma our that blood-based QX to monitoring using X company, in team in
can contributions deliver previous our in efficient, mentioned lab cash is committed our over to set we’re that XXXX. positive drive to and current services with of pharma gross our projects, course P&L calls, the margins As incredibly
for near-term and channel. as well believe revenue XXXX strategic of pharma our support growing exciting We ourselves and was throughout We an cancer. for future a laid sales an operations engines portfolio with derisked in to data business momentum DetermaRx, new provides confident a growth year establishing for our will like lung clearly our immediate foundation ‘XX. leaders we’ve diversified in immediate, milestone remain which while Oncocyte. our Just strong growth milestones engine, as services tests our development incredibly as look and and forward sharing for long-term of early-stage
continued turn and financials, believe for on entire the of an call stay thank in dedication ensure Mitch I over team unprecedented our for work track our who remain our to tests to hard physicians, a partners of Before Oncocyte incredible payers. thanks advancing be We we transformative novel of goal our want environment patients, to their for team, review I each will progress, committed for made for strategic and to this initiatives. we that to
over to like to review call turn Now, financials. the to Mitch I’d Mitch? the
